ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2335

Increased TSLP Expression in Joints of Rheumatoid Arthritis Patients Causes Increased Activation of Intra-Articular Myeloid Dendritic Cells with Enhanced Th1 and Th17 Cell Activity

F.M. Moret1, C.E. Hack2, T.R.D.J. Radstake3, J.W.J. Bijlsma1, F.P.J.G. Lafeber1 and J.A.G. van Roon4, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Immunology, UMC Utrecht, Utrecht, Netherlands, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cytokines, dendritic cells and rheumatoid arthritis (RA), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Thymic stromal lymphopoietin (TSLP) is well known for its potent activation of myeloid dendritic cells (mDCs) to induce Th2-mediated immune responses. Administration of TSLP in a collagen-induced arthritis model was expected to inhibit Th1 and Th17-driven arthritis by the induction of Th2 activity. However, this resulted in an enhanced severity of inflammation and joint destruction. Additionally, prevention of TSLPR signalling strongly reduced Th17-driven experimental arthritis and immunopathology. The present study determined the levels of TSLP and numbers of TSLPR-expressing mDCs in joints of rheumatoid arthritis (RA) patients as compared to peripheral blood (PB) and studied the capacity of TSLP to induce mDC-dependent T-cell activation.

Methods: TSLP was measured in synovial fluid (SF) of patients with RA (n=50) and osteoarthritis (OA, n=24) by ELISA. CD1c mDC numbers and TSLPR expression on these cells were assessed by FACS analysis in paired samples of SF and PB from RA patients (n=9). CD1c mDCs, isolated from PB as well as SF of RA patients (n=6), were stimulated with TSLP for 20 hours and cytokine production was measured by multiplex immunoassay (measuring 51 cytokines). Washed TSLP-activated CD1c mDCs from PB (n=11) and SF (n=5) were added to autologous CD4 T cells in the absence of additional stimuli, cultured for 6 days and subsequently proliferation was measured. Additionally, T-cell cytokine production was measured (by ELISA) upon restimulation with ionomycin/PMA.

Results: TSLP levels in SF of RA patients were significantly increased compared to OA patients (mean 297 vs. 80 pg/ml, resp., p<0.01). mDCs numbers from SF were significantly increased compared to PB (5.0% vs. 0.6%, resp., p<0.01) and expressed increased levels of TSLPR (MFI 24 vs. 15, resp., p<0.01). TSLP significantly stimulated the production of chemokines TARC and MIP1α by mDCs from PB and SF (TARC: PB from 1 to 42 pg/ml, p<0.05 and SF from 26 to 186 pg/ml, p<0.05; MIP1α: PB from 1268 to 5486 pg/ml, p<0.05 and SF from 2776 to 3733 pg/ml, p<0.05). Upon incubation with TSLP, TSLPR-expressing mDCs from PB potently stimulated proliferation of autologous CD4 T cells as compared to unstimulated mDCs (ratio T cell:DC 5:1, from 1503 to 16036 cpm, p<0.01). However, TSLP-mDCs from SF had a strongly increased capacity to activate CD4 T cells (ratio T cell:DC 5:1, from 26395 to 57387 cpm, p<0.05). Enhanced proliferation was associated with increased production of IFNγ (ratio T cell:DC 5:1, PB from 179 to 655 pg/ml, p<0.01 and SF from 601 to 1867 pg/ml, p<0.05), IL-17 (PB from 39 to 353 pg/ml, p<0.05 and SF from 363 to 1382 pg/ml, p<0.05), and IL-4 (PB from 17 to 246 pg/ml, p<0.01 and SF from 193 to 775 pg/ml, n.s.).

Conclusion: Our data indicate that increased intra-articular TSLP concentrations in RA potently activate TSLPR-expressing mDCs from SF to secrete enhanced levels of proinflammatory mediators causing T cell chemotaxis and to potently increase arthritogenic T cell activation. This suggests that TSLP and TSLPR-expressing mDCs could both play an essential role in the immunopathology of RA.


Disclosure:

F. M. Moret,
None;

C. E. Hack,
None;

T. R. D. J. Radstake,
None;

J. W. J. Bijlsma,
None;

F. P. J. G. Lafeber,
None;

J. A. G. van Roon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-tslp-expression-in-joints-of-rheumatoid-arthritis-patients-causes-increased-activation-of-intra-articular-myeloid-dendritic-cells-with-enhanced-th1-and-th17-cell-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology